Pharma and biotech, where a director buy often lands close to trial or regulatory news and the price history around it is worth reading carefully.
62 disclosed insiders purchases across 33 health care companies in the last twelve months, worth $79m. The median buy has returned +5.9% against the market since it was disclosed.
62 buys · $79m · 33 companies · 39 insiders · median alpha +5.9%
63% of that value is SMMT alone.
| Company | Value bought | Buys |
|---|---|---|
| Summit Therapeutics Inc. | $50m | 1 |
| Artiva Biotherapeutics, Inc. | $12m | 1 |
| Burning Rock Biotech Ltd | $6.1m | 6 |
| PROTHENA CORP PUBLIC LTD CO | $3.1m | 5 |
| Pelthos Therapeutics Inc. | $986k | 1 |
| TREACE MEDICAL CONCEPTS, INC. | $704k | 5 |
| GE HealthCare Technologies Inc. | $642k | 1 |
| Oncology Institute, Inc. | $589k | 6 |
| BOSTON SCIENTIFIC CORP | $554k | 4 |
| HARROW, INC. | $407k | 2 |
| Conexeu Sciences Inc. | $338k | 1 |
| PHIBRO ANIMAL HEALTH CORP | $318k | 1 |
| Immunome Inc. | $288k | 3 |
| Shattuck Labs, Inc. | $250k | 1 |
| ORASURE TECHNOLOGIES INC | $225k | 3 |
| Ardent Health, Inc. | $186k | 2 |
| Medline Inc. | $171k | 1 |
| Larimar Therapeutics, Inc. | $167k | 1 |
| DENTSPLY SIRONA Inc. | $165k | 2 |
| Tonix Pharmaceuticals Holding Corp. | $117k | 2 |
Rolling twelve months of disclosed purchases. Median alpha is measured against the market from the disclosure-day close — the first price a reader could have paid — not from the insider's own entry, and is marked to the latest cached close. Past performance is not a reliable indicator of future results.